{
    "clinical_study": {
        "@rank": "161419", 
        "arm_group": [
            {
                "arm_group_label": "Raylis", 
                "arm_group_type": "Experimental", 
                "description": "This arm (10 men with symptoms of prostatostasis) will get \"Raylis\" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
            }, 
            {
                "arm_group_label": "standard prostatostasis therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis"
            }, 
            {
                "arm_group_label": "Raylis plus standard prostatostasis therapy", 
                "arm_group_type": "Experimental", 
                "description": "This arm (20 men with symptoms of prostatostasis) will get \"Raylis\" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy of Phytotherapy \"Raylis\" (Ginseng\n      Root Powder 50 mg, False Ginseng Root Powder 50 mg, Codonopsis Root Powder 50 mg, Astragalus\n      Membranaceus Root Powder 50 mg, Epimedium Alpinum Herbal Extract 100 mg) In Congestive\n      Processes Of The Pelvic Organs (Prostatostasis) In Congestive Processes Of The Pelvic Organs\n      (Prostatostasis)"
        }, 
        "brief_title": "Efficacy Study of Phytotherapy \"Raylis\" In Congestive Processes Of The Pelvic Organs (Prostatostasis)", 
        "condition": [
            "Congestive Processes Of The Pelvic Organs (Prostatostasis)", 
            "Erectile Dysfunction", 
            "Sexual Function"
        ], 
        "condition_browse": {
            "mesh_term": "Erectile Dysfunction"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 20-60 years\n\n          -  Symptoms of prostatostasis lasting for at least 3 months during the past 6 months:\n\n          -  Pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s,\n             average urinary flow rate of less than 12 ml / sec)\n\n          -  TRUS Prostate volume more than 22 ml at TRUS\n\n          -  TRUS picture of Prostatostasis\n\n          -  I-PSS 7-20\n\n          -  IIEF-5) - 12-21\n\n        Exclusion Criteria:\n\n          -  Contraindications and limitations to use of the drug Raylis listed in the\n             instructions for medical use *\n\n          -  Diabetes mellitus (type 1 and type 2, decompensation)\n\n          -  Neurogenic disorders (acute cerebral circulatory disorders, Alzheimer's disease,\n             spinal cord injury)\n\n          -  A history of pelvic trauma\n\n          -  Patients who had undergone radical prostatectomy and other surgical interventions on\n             the pelvic organs\n\n          -  Concomitant use of supplements to improve the erectile function, use of the\n             anti-androgens, anti-depressants, finasteride.\n\n          -  Diagnosed BPH\n\n          -  Current participation in a clinical trial and / or study medication for 30 days prior\n             to inclusion\n\n          -  Any form of substance abuse, mental disorder or condition which, in the opinion of\n             the investigator, may complicate communication with the researcher.\n\n          -  The inability or unwillingness to comply with the scheme of visits according to\n             protocol."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866995", 
            "org_study_id": "MHCL-01-15052013"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Raylis", 
                    "Raylis plus standard prostatostasis therapy"
                ], 
                "description": "\"Raylis\" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)", 
                "intervention_name": "\"Raylis\"", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "standard prostatostasis therapy", 
                    "Raylis plus standard prostatostasis therapy"
                ], 
                "intervention_name": "standard prostatostasis therapy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ginseng", 
            "Prostatostasis", 
            "Erectile Dysfunction"
        ], 
        "lastchanged_date": "May 29, 2013", 
        "location": {
            "contact": {
                "last_name": "Yuliya Tishova, MD PhD", 
                "phone": "+79032213276"
            }, 
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "zip": "123242"
                }, 
                "name": "Clinic Of Men's Health and Couple Longevity"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 3 Study of Phytotherapy \"Raylis\" In Congestive Processes Of The Pelvic Organs (Prostatostasis)Caused By Decrease Of Sexual Activity In Men.", 
        "other_outcome": {
            "measure": "IPSS", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "yulya_tishova@mail.ru", 
            "last_name": "Yuliya Tishova, MD PhD", 
            "phone": "+79032213276"
        }, 
        "overall_official": {
            "affiliation": "Clinic of Men's Health and Couple Longevity, str Zoologicheskaya, 2-7 Moscow Russia", 
            "last_name": "Svetlana Kalinchenko, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "TRUS prostate", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866995"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Uroflowmetry", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "The Clinic of Men's Health and Couple Longevity, Russia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Clinic of Men's Health and Couple Longevity, Russia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}